Physician profile
Ray Fenley
NPI 1841877024
$759.58
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $183.99 | 2023 | Invega Trinza, Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $85.09 | 2022-2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $82.71 | 2022-2023 | Ingrezza |
| Abbvie INC. | $66.13 | 2022-2023 | |
| Neuronetics, INC. | $47.50 | 2023 | Neurostar Tms Therapy System |
| Lundbeck LLC | $46.40 | 2022-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $44.47 | 2022 | |
| Vanda Pharmaceuticals INC. | $42.88 | 2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $40.91 | 2023 | Trintellix |
| Corium, LLC | $24.86 | 2022 | |
| Indivior INC. | $24.33 | 2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $20.58 | 2023 | Austedo |
| Axsome Therapeutics, INC. | $19.75 | 2023 | Auvelity |
| Noven Therapeutics, LLC | $15.04 | 2023 | Secuado |
| Idorsia Pharmaceuticals US INC | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Fenley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.